Immunoglobulin for intravenous injection refers to the globulin that is specially used for intravenous infusion by precipitating and reprocessing the components extracted from the plasma of healthy people by the low-temperature ethanol method to remove the anti-complement activity and refining it through steps such as pasteur inactivation virus.
There are five types of immunoglobulins, including IgG, IgA, IgM, IgD, and IgE. IgG antibodies are globulins with antibody-like structure or antibody activity, which are antibodies for re-immune response and the most important antibodies against pathogenic microorganisms in body fluids. It is the only immunoglobulin that crosses the placental barrier and has the ability to neutralize toxins and viruses. If the body is found to have antibodies to a certain disease, it means that you can avoid contracting this disease and have immunity to this disease. For example, if the IgG antibody is positive, it means that you have been infected with the virus.
Intravenous immunoglobulins can be divided into liquid formulations and powders. At present, the most widely used is immunoglobulin liquid preparations, which accounted for 86.75% of the market share in 2020, while powders only accounted for 13.25% of the market. Immunoglobulin liquid preparations can enhance the body's immunity, play a role in resisting viruses, bacteria and other microorganisms, and antibiotics, antiviral or antifungal drugs, can enhance the effect of these drugs, can improve the level of IgG in the patient's body, can treat primary immunoglobulin deficiency, secondary immunoglobulin deficiency diseases, such as severe infection, sepsis, autoimmune diseases, including primary thrombocytopenic purpura, autoimmune anemia, etc.
Analysis of the current situation and prospect of the global intravenous immunoglobulin industry industry
North America is the largest revenue market for the global intravenous immunoglobulin industry, accounting for more than half of the global market. In 2020, the market share of the industry in North America was 60.99%, however, its market share will decrease during the forecast period and is expected to decrease to 60.35% by 2025. Europe and Asia-Pacific ranked second and third with a market share of 22.64% and 14.54%, respectively, while South America, the Middle East and Africa had a very low market share of 1.10% and 0.73% in this industry. The Asia-Pacific region is expected to be the fastest growing market for the industry, as its market share is increasing year by year and is expected to expand during the year, with the market share of the global intravenous immunoglobulin industry expected to grow to 15.73% by 2025.
The top three companies in the industry are CSL Behring, Grifols and Octapharma, with three companies from Switzerland, the United States and Australia. CSL Behring is a company that develops, manufactures and markets protein-based therapeutics for bleeding disorders, rehydration, hereditary angioedema, immunoglobulins, lung and wound healing plasma-derived and recombinant therapies. Grifols develops, manufactures and markets plasma derivatives, intravenous therapies, enteral nutrition, diagnostic systems and medical materials. Octapharma develops, manufactures and markets medicines derived from human proteins. The Company provides biopharmaceutical products and therapies for hematology, critical care and emergency medicine, and immunotherapy. In 2020, these three companies accounted for 16.75%, 8.74% and 5.06% of the global intravenous immunoglobulin industry. The total market share of the top 3 companies is 30.55%, and the industry concentration is average.
Research data shows that the total market value of the global intravenous immunoglobulin industry in 2015 was 5.393 billion US dollars, and the industry developed rapidly from 2015 to 2020, and by 2020, the total market value has reached 10.346 billion US dollars. On the basis of this data, combined with the development law of the industry, we have carried out a series of function operations to scientifically deduce the data for the next five years. Finally, it can be predicted that the annual value of the global injectable immunoglobulin industry will continue to rise from 2021 to 2025, growing to $20.088 billion by 2025, and the compound annual growth rate is forecast to be 9.70% from 2021 to 2025.
After the epidemic, the awareness of public health management has been continuously enhanced, the upstream plasma mining has stagnated, and the market for injection immunoglobulin industry is in short supply
In 2020, due to the impact of the new crown epidemic, the development of many industries slowed down or stagnated significantly, but the epidemic has promoted the development of the global intravenous immunoglobulin industry to a certain extent. According to the data, the total market value of the industry in 2020 was US$10.346 billion, an increase of US$2.221 billion or 21.47% compared with 2019. Immunity is a very important condition in the fight against the coronavirus. As a result of the pandemic, the public has become more aware of immunization and early treatment, treatment and disease prevention. After the end of the epidemic, people's demand for health management and healthcare will also be higher, which will promote the growth of medical consumption and open up the market from the demand side. In addition, people's understanding of the prognosis and harm of diseases is also increasing, and the research and development of related drugs and reagents will surely receive more attention. This will allow the intravenous immunoglobulin (IVIg) industry to attract more attention, promote product innovation and development, stimulate market vitality, and more pharmaceutical companies are expected to strengthen the R&D and manufacturing of such drugs.
However, the coronavirus epidemic has caused plasma donation to be largely stopped at plasma collection stations around the world. Due to the quarantine period, the stockpiled plasma must be re-qualified after 3 months before it can be put into production. If the epidemic prevention and control situation in Europe and the United States continues to be uncertain, the resumption of plasma mining will become more difficult, which will lead to a shortage of plasma supply. In this situation where demand outstrips supply, the price of intravenous immunoglobulin (IVIg) products will rise rapidly in the short term.
In the face of the impact of the pandemic, established chronic disease drugs such as intravenous immunoglobulin (IVIg) have been used in the prescribing mechanism with a change (a three-month long-term prescription at a time) to change the sales channel and successfully reduce the significant impact of the pandemic, helping the industry recover quickly from the negative effects of the pandemic. In conclusion, the pharmaceutical market is relatively strong. At the same time, as hospitals continue to open up, the market will gradually recover after the gradual increase in patient confidence.